BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 29657135)

  • 1. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pralsetinib: First Approval.
    Markham A
    Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
    Bruce JY; Bible KC; Chintakuntlawar AV
    Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
    [No Abstract]   [Full Text] [Related]  

  • 6. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
    Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
    Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
    Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
    Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Landscape of Acquired Resistance to Osimertinib in
    Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
    Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. REToma: a cancer subtype with a shared driver oncogene.
    Kohno T; Tabata J; Nakaoku T
    Carcinogenesis; 2020 Apr; 41(2):123-129. PubMed ID: 31711124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Human-Derived
    Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
    Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision therapy for RET-altered cancers with RET inhibitors.
    Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
    Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
    Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
    Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
    Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].
    Zheng Y; Jiang W; Chen D; Li Y; Dai L; Huang L; Wang M
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):591-597. PubMed ID: 34120433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
    La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
    Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.